A phase 1 trial using miR-16 mimic incorporated with epidermal growth factor receptor (EGFR) targeting antibody called TargomiR, was used for patients with either recurrent malignant pleural mesothelioma or non-small cell lung cancer [159,160]. Here, EGFR is linked to non-small cell lung carcinoma.